# Longitudinal evidence of technology-enhanced, individualized neuromotor rehabilitation on autonomy, cognition, quality of life, and psychological well-being: Pilot multi-sample study

**Authors:** Francesco Zanatta, Patrizia Steca, Cira Fundarò, Anna Giardini, Chiara Ferretti, Giovanni Arbasi, Roberta Adorni, Marco D’Addario, Antonia Pierobon, Joshua (Sung) H. You, Hiroki Annaka, Hiroki Annaka, Hiroki Annaka

PMC · DOI: 10.1371/journal.pone.0344472 · PLOS One · 2026-03-13

## TL;DR

This pilot study shows that personalized technology-based rehabilitation improves not only physical recovery but also cognition, mental health, and quality of life in patients with stroke, Parkinson’s Disease, and osteoarthritis.

## Contribution

The study provides longitudinal evidence of the multi-domain benefits of technology-enhanced, individualized neuromotor rehabilitation in diverse patient populations.

## Key findings

- Significant improvements in autonomy, cognition, and psychological well-being were observed post-intervention in patients receiving technology-enhanced rehabilitation.
- Sustained improvements in health-related quality of life and reduced anxiety and depression were maintained at 6-month follow-up.
- Technology-enhanced rehabilitation showed greater short-term effects on well-being compared to standard training in stroke and osteoarthritis patients.

## Abstract

Over the last decades, neuromotor rehabilitation programs have integrated multidisciplinary approaches with the implementation of emerging technology (e.g., robotics and virtual reality – VR), to effectively target recovery complexity. While this strategy supported patient’s physical improvement, little evidence has been reported regarding the widespread effects on non-motor rehabilitation outcomes.

A prospective, two-arm, non-randomized study design was adopted to provide pilot feasibility evidence on the multi-domain impact of personalized technology-enhanced neuromotor rehabilitation from convenience sub-samples of patients with stroke, Parkinson’s Disease (PD), and osteoarthritis (OA). Technological intervention consisted of the integrated use of robot-assisted and/or VR-based exercises, individualized based on patient’s diagnosis and rehabilitation goals. Study outcomes included patient’s functional status (autonomy in ADLs, risk of falls), cognition (attention and executive functions, memory, verbal fluency), physical and mental health-related quality of life (HRQoL), and psychological status (anxiety and depression symptoms, and well-being) and were compared to patients participating in standard training only. Rehabilitation experience and technology psychosocial impact were also evaluated. Intra- and intergroup comparisons along with general linear models were statistically tested within each sub-sample considered independently over three timepoints (baseline, post-intervention, 6-month follow-up).

At post-intervention, significant multi-domain intra-group improvements were observed within each sub-sample. Between-group differences were found on ADLs autonomy (stroke and PD; p < .05), executive functions (stroke; p < .01), anxiety and depression (OA and PD, respectively; p < .05), and well-being (stroke and OA; p < .05). Interaction effects (time x group) were significant only on well-being variables in stroke (p = .01) and OA (p = .02), evidencing wider short-term effects of technology-enhanced programs compared to standard training. At 6-month, significant time effects indicating sustained improvements over the three timepoints were estimated on HRQoL within each sub-sample (p < .05) and, additionally, on anxiety and depression in stroke (p = .02) and OA (p < .001). Interaction effects emerged only on physical HRQoL in OA (p = .02), along with significant between-group differences on HRQoL and anxiety and depression in OA (p < .05) and PD (p = .01), respectively.

Further full-scale trials are warranted to confirm the longitudinal trends observed in this pilot study and to further investigate the potential multi-domain benefits of multidisciplinary and technology-integrated recovery approaches across different clinical populations.

ClinicalTrials.gov ID: NCT05399043.

## Linked entities

- **Diseases:** stroke (MONDO:0005098), Parkinson’s Disease (MONDO:0005180), osteoarthritis (MONDO:0005178)

## Full-text entities

- **Diseases:** impairment (MESH:D060825), injury (MESH:D014947), Post-stroke (MESH:D020521), depression (MESH:D003866), falls (MESH:C537863), neoplastic diseases (MESH:D004194), Mental Disorders (MESH:D001523), Anxiety Disorder (MESH:D001008), Cognitive disorders (MESH:D003072), impulse control disorders (MESH:D007174), PD (MESH:D010300), mood disorders (MESH:D019964), muscles weakness (MESH:D018908), aphasia (MESH:D001037), pain (MESH:D010146), psychosis (MESH:D011618), neurological sub-acute (MESH:D000071072), neurological sub (MESH:D007246), neurodegenerative (MESH:D019636), rigidity (MESH:D009127), OA (MESH:D010003), knee injury (MESH:D007718), neurological impairment (MESH:D009422), neurological diseases (MESH:D020271), non-motor impairments (MESH:C580335), polymyalgia rheumatica (MESH:D011111), chronic obstructive pulmonary disease (MESH:D029424), diabetes (MESH:D003920), dementia (MESH:D003704), musculoskeletal (MESH:D009140), atrial fibrillation (MESH:D001281), progressive disability (MESH:D018450), impaired coordination (MESH:D001259), ICD (MESH:D008310), disability (MESH:D009069), coronary heart disease (MESH:D003327), gait dysfunctions (MESH:D020233), paralysis (MESH:D010243), loss of joint functions (MESH:D006315), chronic pain (MESH:D059350), Fatigue (MESH:D005221), respiratory disease (MESH:D012140), hypertension (MESH:D006973), motor deficits (MESH:D009461), heart failure (MESH:D006333), GAD-7 (MESH:C000726808), osteoporosis (MESH:D010024), bradykinesia (MESH:D018476), mental health condition (MESH:D000071069), obstructive sleep apnea (MESH:D020181), inflammations (MESH:D007249), tremor (MESH:D014202), polyneuropathy (MESH:D011115), language disorders (MESH:D007806), ischemic heart disease (MESH:D017202), postural instability (MESH:D054972), hyperuricemia (MESH:D033461), memory difficulties (MESH:D008569), motor impairments (MESH:D000068079), Anxiety and depression (MESH:D001007)
- **Chemicals:** PONE-D-24-33691R2 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987491/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12987491/full.md

## References

100 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987491/full.md

---
Source: https://tomesphere.com/paper/PMC12987491